<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466726</url>
  </required_header>
  <id_info>
    <org_study_id>CML 0206</org_study_id>
    <secondary_id>GIMEMA-CML0206</secondary_id>
    <secondary_id>EUDRACT-2006-006189-40</secondary_id>
    <secondary_id>EU-20724</secondary_id>
    <nct_id>NCT00466726</nct_id>
    <nct_alias>NCT00452933</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia</brief_title>
  <acronym>CML 0206</acronym>
  <official_title>Phase II Multicenter Study of P210-B3A2 Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Response With Persistent Molecular Residual Disease During Imatinib Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response
      to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of
      immune cells found in bone marrow or peripheral blood. Giving booster vaccinations may make a
      stronger immune response and prevent or delay the recurrence of cancer.

      PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients
      with Philadelphia chromosome-positive chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the activity of bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine
           (CMLVAX100), in terms of peripheral blood bcr-abl/abl ratio reduction, in patients with
           Philadelphia chromosome-positive chronic myelogenous leukemia.

      Secondary

        -  Determine the reduction of molecular residual disease at 3 months in patients treated
           with this vaccine.

        -  Determine the reduction of molecular residual disease at 12 months in patients treated
           with maintenance boosts of this vaccine.

        -  Determine the rate of complete molecular response at any time after vaccination.

        -  Determine in vivo and in vitro peptide-specific immune response induced by the vaccine.

      OUTLINE: This is a prospective, nonrandomized, open-label, multicenter study.

      Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1 and 2 and bcr-abl
      p210-b3a2 breakpoint-derived pentapeptide vaccine (CMLVAX100) SC on day 2. Treatment repeats
      every 2 weeks for 6 courses. Patients then receive CMLVAX100 SC once monthly for 3 months and
      then once every 3 months for 6 months (for a total of 1 year). Patients may receive
      additional CMLVAX100 SC every 6 months for at least 3 years. Treatment continues in the
      absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 69 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at 6 and 9 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of molecular residual disease at 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of molecular residual disease at 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete molecular response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo and in vitro peptide-specific immune response induced by vaccination</measure>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic myelogenous leukemia (CML) meeting the following criteria:

               -  Philadelphia chromosome positive disease

               -  b3a2 breakpoint mutation

          -  Prior treatment with conventional imatinib mesylate for ≥ 18 months required

               -  Complete cytogenetic response documented on ≥ 2 different examinations

                    -  Persistence of molecularly detectable residual disease (any level of bcr-abl
                       transcript)

               -  Patients continue to receive imatinib mesylate at the same dose (conventional
                  treatment) during study treatment

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  Creatinine ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No severe active infection or other serious medical illness that would preclude study
             completion

          -  No known immunodeficiency

          -  No autoimmune disorders

        PRIOR CONCURRENT THERAPY:

          -  No concurrent immunosuppression or systemic immunosuppressive medication

          -  No concurrent dose escalation of imatinib mesylate

          -  No other concurrent investigational products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Bocchia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nouvo Policlinico &quot;LE SCOTTE'</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universita Degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale 'Ferrarotto'</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale A. Pugliese</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federico II University Medical School</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale S. Luigi at University of Torino</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>spedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi &quot;La Sapeinza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia - Presidio Ospedaliero N. Giannetasio - Azienda ASL 3</name>
      <address>
        <city>Rossano (CS)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvo Policlinico &quot;LE SCOTTE'</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>February 17, 2015</last_update_submitted>
  <last_update_submitted_qc>February 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 21, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

